Japanese drugmaker Daiichi Sankyo Co said on Tuesday its Indian unit Ranbaxy Laboratories Ltd has suspended shipment of pharmaceutical ingredients produced at its Toansa and Dewas plants.
In January, the US Food and Drug Administration banned the Toansa plant, a key supplier of ingredients to the generic drugmaker's US factory, from sending its products to the United States due to manufacturing violations.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
